| Serial Number | 90660096 |
| Word Mark | MYRIAD GENETICS |
| Filing Date | Wednesday, April 21, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, August 8, 2023 |
| Registration Number | 7133864 |
| Registration Date | Tuesday, August 8, 2023 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, November 30, 2021 |
| Description of Mark | The mark consists of the word "MYRIAD" with the "M" appearing as a capital letter formed by four (4) lines that do not touch, and the remainder of the word appearing in lowercase letters, and the word "GENETICS" directly below "MYRIAD" appearing in lowercase letters. |
| Goods and Services | Genetic testing services for diagnostic or treatment purposes; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing, monitoring, and reporting services; internet-based health care information services; providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing, individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis and medical and pharmaceutical consultation services related thereto, namely, discussion and interpretation with clients of medical test results and medical analysis related thereto; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion and each medication's receptor activity, mechanism of action, and pathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication selection, and treatment options and choices for patients, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; and medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications |
| NOT AVAILABLE | "GENETICS" |
| Goods and Services | Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; providing temporary use of non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; scientific research analysis and consulting services which use bioinformatics; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, July 28, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | Tuesday, May 4, 2021 |
| First Use In Commerce Date | Tuesday, May 4, 2021 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, July 28, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | Tuesday, May 4, 2021 |
| First Use In Commerce Date | Tuesday, May 4, 2021 |
| Party Name | Myriad Genetics, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Salt Lake City, UT 84116 |
| Party Name | Myriad Genetics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Salt Lake City, UT 84108 |
| Party Name | Myriad Genetics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Salt Lake City, UT 84108 |
| Event Date | Event Description |
| Saturday, April 24, 2021 | NEW APPLICATION ENTERED |
| Wednesday, July 28, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, September 6, 2021 | ASSIGNED TO EXAMINER |
| Thursday, July 29, 2021 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, September 8, 2021 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 8, 2021 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 8, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, October 25, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, October 25, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Monday, October 25, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, October 25, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Monday, October 25, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 10, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 30, 2021 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 30, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 25, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, January 27, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, January 27, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, January 27, 2022 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Thursday, January 27, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, June 17, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, June 17, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, June 17, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, June 17, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, June 17, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, July 25, 2022 | SOU TEAS EXTENSION RECEIVED |
| Monday, July 25, 2022 | SOU EXTENSION 1 FILED |
| Monday, July 25, 2022 | SOU EXTENSION 1 GRANTED |
| Wednesday, July 27, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, December 15, 2022 | SOU TEAS EXTENSION RECEIVED |
| Thursday, December 15, 2022 | TEAS REQUEST TO DIVIDE RECEIVED |
| Thursday, December 15, 2022 | SOU EXTENSION 2 FILED |
| Thursday, December 15, 2022 | DIVISIONAL REQUEST RECEIVED |
| Wednesday, January 25, 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, February 3, 2023 | SOU EXTENSION 2 GRANTED |
| Friday, February 3, 2023 | DIVISIONAL PROCESSING COMPLETE |
| Saturday, February 4, 2023 | CORRECTED NOA E-MAILED |
| Saturday, February 4, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, June 27, 2023 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, June 27, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, June 27, 2023 | SOU EXTENSION 3 FILED |
| Tuesday, June 27, 2023 | USE AMENDMENT FILED |
| Friday, June 30, 2023 | SOU EXTENSION 3 GRANTED |
| Friday, June 30, 2023 | STATEMENT OF USE PROCESSING COMPLETE |
| Saturday, July 1, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, July 3, 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Tuesday, July 4, 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Wednesday, July 26, 2023 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Tuesday, August 8, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, August 8, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, July 9, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, July 9, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, July 9, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, July 9, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, July 9, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |